EVALUATION OF THE BRONCHOPROTECTIVE EFFECT OF ARFORMOTEROL IN CHILDREN WITH

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 本研究正在研究阿福特罗治疗运动诱发支气管痉挛[EIB]。在这项研究中，我们比较了阿福特罗吸入溶液、福莫特罗干粉吸入剂和安慰剂[无活性药物]。 EIB在儿童和年轻人中很常见，可以通过药物预防。福莫特罗干粉吸入器装置已被FDA批准用于成人和5岁及以上儿童哮喘的维持[每日]治疗和EIB的预防。福莫特罗由两种化合物组成：解释这一点的最好方法是将这两种化合物想象成你的手。 福莫特罗是左手和右手的镜像，压在一起，但只有右手是活动的[R，R-福莫特罗]，而左手[称为S，S-福莫特罗]在那里陪伴它。 R，R-福莫特罗也称为阿福特罗。阿福特罗吸入溶液经FDA批准用于慢性阻塞性肺疾病[COPD]成人患者支气管收缩的维持治疗。我们想知道吸入阿福特罗是否对预防EIB有效。这是一项在EIB儿童中进行的阿福特罗III期研究，这意味着阿福特罗用于EIB是实验性的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is studying the use of arformoterol for exercise induced bronchospasm [EIB]. In this study we compare arformoterol inhalation solution to formoterol dry powder inhaler, and placebo [no active drug]. EIB is common in children and young adults and it can be prevented by using medications. Formoterol in a dry powder inhaler device has been approved by the FDA to be used in the maintenance [daily] treatment of asthma and in the prevention of EIB in adults and children 5 years of age and older. Formoterol is made of two chemical compounds: The best way to explain this is to think of these two chemical compounds as your hands. Formoterol is both the left and right hand, mirror images, pressed together but only the right hand is active [R,R-formoterol], and the left hand [called S,S-formoterol] is there keeping it company. R,R-formoterol is also called arformoterol. Arformoterol inhalation solution is approved by the FDA for maintenance treatment of bronchoconstriction in adult patients with chronic obstructive pulmonary disease [COPD]. We would like to know if arformoterol inhalation will work for the prevention of EIB. This is a Phase III study of arformoterol in children with EIB, meaning that the use of arformoterol for EIB is experimental.